Joao Carvalho-Ramalho

Porto, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Large-scale DNA methylation profiling of urological cancers identifies shared and cancer-specific methylation signatures, and reveals differentially activated pathways for therapeutic targeting.

Large-scale DNA methylation profiling of urological cancers identifies shared and cancer-specific methylation signatures, and reveals differentially activated pathways for therapeutic targeting.

Journal: Clinical and translational medicine

Published: July 08, 2025

Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction.

Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction.

Journal: Frontiers in oncology

Published: December 05, 2018

Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype.

Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype.

Journal: Cancer cell international

Published: November 16, 2018

Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case.

Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case.

Journal: Experimental and molecular pathology

Published: April 04, 2018

A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97.

A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97.

Journal: Clinical epigenetics

Published: February 01, 2018

Methylation-Specific PCR.

Methylation-Specific PCR.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: December 11, 2017

High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.

High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.

Journal: Urologic oncology

Published: June 25, 2017

Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer.

Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer.

Journal: Journal of hematology & oncology

Published: November 07, 2016

Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.

Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.

Journal: Cancer letters

Published: August 14, 2016

MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma.

MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma.

Journal: British journal of cancer

Published: August 12, 2016

MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.

MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.

Journal: Molecular cancer

Published: July 17, 2016

Deciphering the function of non-coding RNAs in prostate cancer.

Deciphering the function of non-coding RNAs in prostate cancer.

Journal: Cancer metastasis reviews

Published: May 26, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026